Atmo Biosciences appoints world-renowned gastroenterologist as Medical Advisory Board chair

Latest News

Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, has announced the appointment of gastroenterologist Professor Eamonn Quigley as the chair of its Medical Advisory Board (MAB).

Professor Quigley is the David M. Underwood chair of Medicine in Digestive Disorders and chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas.

He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome and its link to the gut microbiome.

“I am thrilled to have someone of Professor Quigley’s standing join our MAB as Chair,” said Atmo Biosciences CEO Malcolm Hebblewhite.

“Eamonn is an internationally respected leader in gastroenterology. His ongoing research and thought leadership in the areas of motility and Small Intestinal Bacterial Overgrowth (SIBO) will be invaluable as we seek to develop these two key areas of focus in the U.S. and beyond”.

Professor Quigley said, “I am always excited by the promise of novel technologies that explore the gut microenvironment and the interactions between diet and the microbiome in particular. Atmo’s technology has the potential to serve as a valuable tool in both gastroenterological research and clinical practice. I am looking forward to sharing my insights with the other members of the Board and with Atmo.”

Professor Quigley succeeds Professor Peter Gibson. Mr Hebblewhite said, “I want to thank Professor Gibson for the considerable contributions he has made to Atmo’s clinical development and the MAB to date. While he is stepping down as Chair, Peter will continue to play an active role with Atmo and the MAB, and I look forward to his ongoing involvement.”